MONTREAL, CANADA -- (MARKET WIRE) -- January 24, 2007 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced the commercial launch of PravASA®, an innovative, cost-effective product which combines pravastatin, a cholesterol-lowering medication, and delayed-release ASA, a platelet aggregation inhibitor, in a single package. PravASA® is a convenient combination package which, based upon a U.S. study, increases patient compliance. In addition, PravASA® offers excellent value for patients who are already being prescribed pravastatin and ASA separately, as PravASA® is priced the same as generic pravastatin. In essence, patients are receiving the benefit of the compliance package with the ASA at no additional cost.